ICS Publications - CBML

Conferences (10)

    Papers in Proceedings (full-paper reviewed)

  1. Spanakis, M., Sfakianakis, S.G., Spanakis, E.G., Kallergi, G., & Sakkalis, V. (2018). PDCA: An Ehealth Service for the Management of Drug Interactions with Complementary and Alternative Medicines. IEEE Conference on Biomedical and Health Informatics (BHI) 2018, Las Vegas, Nevada, USA, 4-7 March 2018., 4-3-2018.
  2. Spanakis, M., Manikis, G., Porwal, S., & Spanakis, E.G. (2017). Developing a context-dependent tuning framework of multi-channel biometrics that combine audio-visual characteristics for secure access in eHealth platform for osteoarthritis management. MobiHealth 2017 - 7th EAI International Conference on Wireless Mobile Communication and Healthcare, November 14-15, 2017, Vienna, Austria, 14-11-2017.
  3. Spanakis, M., Spanakis, E.G., Kondylakis, H., Sfakianakis, S.G., Genitsaridi , I., Sakkalis, V., Tsiknakis, M.N., & Marias, K. (2016). Addressing drug-drug and drug-food interactions through personalized empowerment services for healthcare. 38th Annual International Conference of the IEEE Engineering in Medicine and Biology Society (EMBC 2016).
  4. Spanakis, E.G., Spanakis, M., Karantanas, A., & Marias, K. (2016). Secure Access to Patient's Health Records using SpeechXRays a Multi-Channel Biometrics Platform for User Authentication. 38th Annual International Conference of the IEEE Engineering in Medicine and Biology Society, Orlando, FL, USA, 16-20 August 2016, (pp. 2541-2544). doi: 10.1109/EMBC.2016.7591248. PMID:28268840.
  5. Maniadi, E., Kondylakis, H., Spanakis, E.G., Spanakis, M., Tsiknakis, M.N., Marias, K., & Dong, F. (2013). Designing a digital patient avatar in the context of the MyHealthAvatar project initiative. 13th IEEE International Conference on BioInformatics and BioEngineering (BIBE) 2013.
  6. Spanakis, M., Papadaki, E., Kafetzopoulos, D., Karantanas, A., Maris, Th.G., Sakkalis, V., & Marias, K. (2013). Exploitation of patient avatars towards stratified medicine through the development of in silico clinical trials approaches.  IEEE 13th International Conference on Bioinformatics and Bioengineering (BIBE) 2013.
      Poster presentations (abstract reviewed)

    1. Spanakis, M., Sakkalis, V., & Marias, K. (2015). Application of Simcyp® simulator platform for the assessment of the pharmacokinetic profile of Gd-DOTA regarding its disposition in brain tumors lesions with different vasculature. 24th Annual Meeting of the Population Approach Group in Europe (PAGE), Hersonissos, Crete, Greece,  (1871-6032).
    2. Triviai, I.N. , Zeschke, S., Spanakis, M., Stocking, C., & Kroeger, N. (2015). Genetic HSC Variability Determines the Drivers of Chronic and Acute Phases of Primary Myelofibrosis57th Annual Meeting & Exposition of American Society of Hematology, Blood , (vol. 126, pp. 1629). DOI: http://dx.doi.org/.
    3. Spanakis, M., Spanakis, E.G., Kafetzopoulos, D., Sakkalis, V., Tsiknakis, M.N., Marias, K., & Dong, F. (2015). MyHealthAvatar platform: matching real life patients with the generated virtual profiles from in silico clinical trials24th Annual Meeting of the Population Approach Group in Europe (PAGE), At Hersonissos, Crete, Greece, Volume: ISSN 1871-6032.
    4. Spanakis, M., Oraiopoulou, M.E., Tzamali, E., Sakkalis, V., Maris, Th.G., Papadaki, E., Karantanas, A., & Marias, K. (2014). An in silico estimation of the pharmacokinetics profile and disposition of Gd-DTPA in brain tumor lesions of different vasculature through PBPK models. 11th Congress of the European Association of Neuro-Oncology, Turin, Italy, October 9-12, 2014, 11th Congress of the European Association of Neuro-Oncology, Turin, Italy, October 9-12, 2014 (poster ID P16. 33)(vol. 2, pp. 85-86). (doi:10.1093/neuonc/nou174.328).

              Periodicals (5)

                Journal Articles

              1. Triviai, I.N. , Zeschke, S., Rentel, J., Spanakis, M., Scherer , T., Gabdoulline, R., Panagiota , V., Thol, F., Heuser , M., Stocking, C., & Kröger , N. (2018). ASXL1/EZH2 mutations promote clonal expansion of neoplastic HSC and impair erythropoiesis in PMF.. Leukemia, Springer Nature ( 0887-6924 / 1476-5551 / https://www.nature.com/leu/ ), doi: 10.1038/s41375-018-0159-0.
              2. Spanakis, M., Kontopodis, E., Van Cauter, S., & Marias, K. (2016). Assessment of DCE-MRI parameters for brain tumors through implementation of physiologically-based pharmacokinetic model approaches for Gd-DOTA. J Pharmacokinet Pharmacodyn43(5), 529-547, doi: 10.1007/s10928-016-9493-x. Epub 2016 Sep 19. PubMed PMID: 27647272. http://link.springer.com/article/10.1007/s10928-016-9493-x .
              3. Vizirianakis, I. S., Mystridis, G. A., Avgoustakis, K, Fatouros, D. G., & Spanakis, M. (2016). Enabling personalized cancer medicine decisions: The challenging pharmacological approach of PBPK models for nanomedicine and pharmacogenomics. Oncol Rep. 2016 .
              4. Karavasili, C., Spanakis, M., Papagiannopoulou, D., Vizirianakis, I. S., Fatouros, D. G., & Koutsopoulos, S. (2015). Bioactive self-assembling lipid-like peptides as permeation enhancers for oral drug delivery. J Pharm Sci. 2015104(7).
              5. Spanakis, M., & Marias, K. (2014). In silico evaluation of gadofosveset pharmacokinetics in different population groups using the SimcypΒ® simulator platform. , 2(2), (doi:10.1186/s40203-014-0002-x).

                              Talks (1)

                                  Invited Talks

                                1. Spanakis, M. (2014). Application of the Simcyp® simulator platform for the assessment of tracer kinetics used in DCE-MRI. Simcyp Virtual Seminar 2014 .
                                  Found: 16 publications
                                  Conditions of Use | Privacy Policy